DGAP-Adhoc
Biotest AG: Reduction of guidance
DGAP-Ad-hoc: Biotest AG / Key word(s): Profit Warning
|
The exact financial impact of the one-time effect is currently still being determined. As a precautionary measure, Biotest AG is reducing its EBIT guidance for 2021 from € - 5 to - 10 million to
approximately € - 43 to - 55 million.
Biotest Aktiengesellschaft
Board of Management
Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.com
Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These
statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of
actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily
in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used
for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The preference shares of Biotest AG are listed in the Prime Standard on the Frankfurt stock
exchange.